Brief: Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan
06/10/2025 13:18
Oct 6 (Reuters) - Arcus Biosciences Inc RCUS.N: ARCUS BIOSCIENCES INC - CASDATIFAN DATA BETTER ON ALL EFFICACY MEASURES IN PHASE 1/1B ARC-20 STUDY ARCUS BIOSCIENCES- MEDIAN PROGRESSION-FREE SURVIVAL WAS 12.2 MONTHS, 18-MONTH LANDMARK PFS WAS 43% IN POOLED ANALYSIS OF ALL FOUR MONOTHERAPY COHORTS Source text: ID:nBw2sLMgwa Further company coverage: RCUS.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcus Biosciences
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Arcus Biosciences tumbles on $250 mln share sale
Brief: Arcus Biosciences Announces Pricing Of $250 Million Public Offering Of Common Stock
Arcus Biosciences drops after starting stock offering